[Inhibition of induced thrombocyte aggregation in the presence of endothelial cells by dipyridamole].
Dipyridamole is widely used as a platelet function inhibitory drug. Its effect on platelet aggregation was investigated in a newly developed system, in which platelet aggregation was carried out in the presence of a human endothelial cell monolayer (EC). After iv. injection of 20 mg Dipyridamole platelet aggregation (inducer ADP 5 microM, Collagen 5 micrograms) was totally inhibited. The EC dependent antiaggregatory effect of Dipyridamol could be abolished if EC's were pretreated with 1 mmol ASA for 30 min. Our results, carried out in PRP demonstrate that Dipyridamole inhibits platelet aggregation even in the absence of red blood cells which were supposed to enhance the antiplatelet effect by their reduced adenosine uptake. Anenhanced PGI2 production in the EC's may explain the aggregation inhibiting effect of Dipyridamole in this test system.
Kirchmaier
C M
CM
J.W. Goethe Universität Frankfurt/Main.
Altorjay
J
J
Bellinger
O
O
Breddin
H K
HK
D046508:Culture Techniques; D004176:Dipyridamole / Q000494:pharmacology*; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects* / Q000502:physiology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*
D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole
Hemmung der induzierten Thrombozytenaggregation in Gegenwart von Endothelzellen durch Dipyridamol.